Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.61USD
20 Jun 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.61
Open
$1.62
Day's High
$1.63
Day's Low
$1.58
Volume
704,071
Avg. Vol
1,378,623
52-wk High
$2.75
52-wk Low
$0.91

Select another date:

Wed, May 9 2018

BRIEF-Novavax Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novavax Reports Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S

BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019

* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

BRIEF-Novavax Inc Q4 Loss Per Share $0.16

* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Novavax Inc Promotes John Trizzino To CFO Role

* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER

BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018

* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018

BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln

* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:

BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock

* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING‍​ Source text: (http://bit.ly/2Edci1c) Further company coverage:

Select another date: